Method for improving immunity in shrimps

Abstract

The invention discloses a method for improving immunity in shrimps, by administering a double-stranded RNA specific to tyrosine hydroxylase to a shrimp body to improve immunity of the shrimp body, wherein the double-stranded RNA is administered to the shrimp body by injection into the ventral sinus of the cephalothorax of the shrimp body.

Claims

1. A method for improving immunity in shrimps, by administering a double-stranded RNA specific to tyrosine hydroxylase to a shrimp body to improve immunity of the shrimp body.

2. The method for improving immunity in shrimps as claimed in claim 1, wherein the double-stranded RNA has a DNA sequences set forth as SEQ ID NOS: 1 and 2.

3. The method for improving immunity in shrimps as claimed in claim 1, wherein the double-stranded RNA has a DNA sequences set forth as SEQ ID NOS: 3 and 4.

4. The method for improving immunity in shrimps as claimed in claim 1, wherein the double-stranded RNA has a DNA sequences set forth as SEQ ID NOS: 5 and 6.

5. The method for improving immunity in shrimps as claimed in claim 1, wherein the double-stranded RNA is administered to the shrimp body by injection.

6. The method for improving immunity in shrimps as claimed in claim 5, wherein the double-stranded RNA is administered to the shrimp body by injection into the ventral sinus of the cephalothorax.

7. The method for improving immunity in shrimps as claimed in claim 1, wherein the shrimp body is 11.63±2.1 g.

8. The method for improving immunity in shrimps as claimed in claim 1, wherein the double-stranded RNA is administered to the shrimp body in a dosage of 1-6 μg/g of the shrimp body.

9. The method for improving immunity in shrimps as claimed in claim 8, wherein the double-stranded RNA is administered to the shrimp body in a dosage of 5 μg/g of the shrimp body.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The present invention will become more fully understood from the detailed description given hereinafter and the accompanying drawings which are given by way of illustration only, and thus are not limitative of the present invention, and wherein:

(2) FIG. 1a depicts tyrosine hydroxylase activity of white shrimps of groups A1-A4 in trial (A).

(3) FIG. 1b depicts dopamine level of White shrimps of groups A1-A4 in trial (A).

(4) FIG. 1c depicts norepinephrine level of white shrimps of groups A1-A4 in trial (A).

(5) FIG. 2a depicts total haemocyte count of white shrimps of groups B1-B4 in trial (B).

(6) FIG. 2b depicts phenoloxidase activity of white shrimps of groups B1-B4 in trial (B).

(7) FIG. 3a depicts phagocytic activity of white shrimps of groups C1-C4 in trial (C).

(8) FIG. 3b depicts clearance efficiency of white shrimps of groups C1-C4 in trial (C).

(9) FIG. 4 depicts mortality of white shrimps of groups D0-D4 in trial (D).

(10) In the various figures of the drawings, the same numerals designate the same or similar parts. Furthermore, when the term “first”, “second”, “third”, “fourth”, “inner”, “outer”, “top”, “bottom” and similar terms are used hereinafter, it should be understood that these terms refer only to the structure shown in the drawings as it would appear to a person viewing the drawings, and are utilized only to facilitate describing the invention.

DETAILED DESCRIPTION OF THE INVENTION

(11) The shrimp according to the present invention indicates farmed shrimp, including, but not limited to Pacific white shrimp (Litopenaeus vannamei), giant tiger prawn (Penaeus monodon), Kuruma shrimp (Marsupenaeus japonicus), Chinese white shrimp (Fenneropenaeu schinensis), Indian prawn (Fenneropenaeus indicus), greasyback shrimp (Metapenaeus ensis barbata), redtail shrimp (Penaeus penicillatus) and giant river prawn (Macrobrachium rosenbergii).

(12) The double-stranded RNA specific to tyrosine hydroxylase, TH dsRNA for short, according to the present specification indicates the double-stranded RNA having the nucleic acid sequences corresponding to the sequences of tyrosine hydroxylase, such that by administering the TH dsRNA to a shrimp body, the TH dsRNA is able to block tyrosine hydroxylase activity, which can be appreciated by a person having ordinary skill in the art. For example, the TH dsRNA can have, but not limited to, a DNA sequences set forth as SEQ ID NOS: 1 and 2, a DNA sequences set forth as SEQ ID NOS: 3 and 4, or a DNA sequences set forth as SEQ ID NOS: 5 and 6.

(13) The TH dsRNA can be used to block tyrosine hydroxylase activity; and therefore, the TH dsRNA can be administered to the shrimp body in an effective dosage for improving immunity in shrimps.

(14) As an example, the TH dsRNA can be administered to the shrimp body by injection, preferably by injection into the ventral sinus of the cephalothorax. The ventral sinus near the heart is the centrostigma of haemolymph in shrimps, such that the TH dsRNA can flow towards tissues along haemolymph. In this embodiment, the shrimp body with weight of 11.63±2.1 grams is used, and the effective dosage is 1-6 μg/g, preferably is 5 μg/g.

(15) To evaluate the TH dsRNA shows effect on improving immunity in shrimps, as well as decreasing the mortality caused by attack of pathogens, the following trials are preformed.

(16) Trial (A)

(17) White shrimps, Litopenaeus vannamei, are obtained from a commercial farm in Pingtung, Taiwan. The white shrimps are acclimated in the laboratory (freshwater; salinity 20 ppt; temperature 27±1° C.; pH value 8.2-8.7) for 2 weeks before experimentation.

(18) Referring to TABLE 1, the TH dsRNA (SEQ ID NOS: 1 and 2) is administered to white shrimps of group A2 by injection, and the challenge control dsRNAs being not specific to tyrosine hydroxylase are administered to white shrimps of groups A3 and A4 by injection. The dosage for each dsRNA is 5 μg/g. white shrimps of group A1 without dsRNA administration are used as the control. Tyrosine hydroxylase activity is measured 3 days later.

(19) TABLE-US-00001 TABLE 1 Group double-stranded RNA A1 DEPC-H.sub.2O A2 dsRNA specific to tyrosine hydroxylase (SEQ ID NOS: 1 and 2) A3 dsRNA specific to glyceraldehydes 3-phosphate dehydrogenase (SEQ ID NOS: 7 and 8) A4 dsRNA specific to worm non-specific gene (SEQ ID NOS: 9 and 10)

(20) Referring to FIG. 1a, tyrosine hydroxylase activity in white shrimps of group A2 is significantly lower than that of white shrimps of groups A1 and A3-A4.

(21) Moreover, tyrosine hydroxylase is known as an important enzyme to form dopamine and epinephrine, and overexpression of both dopamine and epinephrine may reduce immunity of white shrimps.

(22) Therefore, to demonstrate whether the TH dsRNA improves immunity by inhibiting both dopamine and epinephrine, dopamine level and epinephrine level of white shrimps of groups A1-A4 are measured. Referred to FIGS. 1b and 1c, no significant difference in dopamine and epinephrine levels is observed among white shrimps of groups A1-A4.

(23) Trial (B)

(24) The dsRNA shown in TABLE 2 is administered to white shrimps of groups B2-B4 (dosage: 5 μg/g). After 3 days, hymolymph is withdrawn from the ventral sinus of each shrimp. Immune parameters, such as total haemocyte count (THC) and phenoloxidase (PO) activity in the haemocytes, of white shrimps of groups B1-B4 are measured.

(25) TABLE-US-00002 TABLE 2 Group double-stranded RNA B1 DEPC-H.sub.2O B2 dsRNA specific to tyrosine hydroxylase (SEQ ID NOS: 1 and 2) B3 dsRNA specific to glyceraldehydes 3-phosphate dehydrogenase (SEQ ID NOS: 7 and 8) B4 dsRNA specific to worm non-specific gene (SEQ ID NOS: 9 and 10)

(26) Referring to FIGS. 2a and 2b, immune parameters of white shrimps of group B2 are higher compared to those of white shrimps of groups B1 and B3-B4, indicating the administration of the TH dsRNA improves immunity of white shrimps.

(27) Trial (C)

(28) The dsRNA shown in TABLE 3 is administered to white shrimps of groups C2-C4 (dosage: 5 μg/g). After 3 days, V. alginolyticus bacterial suspension is used to challenge white shrimps of groups C1-C4 (dosage: 2*10.sup.5 CFU/shrimp) for 1.5 hours. Hymolymph is withdrawn from the ventral sinus of each shrimp. For the susceptibility of white shrimps received TH dsRNA against V. alhinolyticus infection, phagocytic activity and clearance efficiency of white shrimps of groups C1-C4 are measured.

(29) TABLE-US-00003 TABLE 3 Group double-stranded RNA C1 DEPC-H.sub.2O C2 dsRNA specific to tyrosine hydroxylase (SEQ ID NOS: 1 and 2) C3 dsRNA specific to glyceraldehydes 3-phosphate dehydrogenase (SEQ ID NOS: 7 and 8) C4 dsRNA specific to worm non-specific gene (SEQ ID NOS: 9 and 10)

(30) Referring to FIGS. 3a and 3b, phagocytic activity and clearance efficiency are significantly higher in white shrimps of group C2 than in white shrimps of groups C1 and C3-C4, indicating the administration of the TH dsRNA is helpful to deplete V. alginolyticus in hymolymph.

(31) Trial (D) V. alginolyticus Challenging Test

(32) For the susceptibility of white shrimps received TH dsRNA against V. alhinolyticus infection, the dsRNAs shown in TABLE 4 are administered to white shrimps of groups D2-D4 (dosage: 5 μg/g). After 3 days, V. alginolyticus bacterial suspension is used to challenge white shrimps of groups D1-D4 (dosage: 2*10.sup.5 CFU/shrimp). The mortality is recoded at 0, 6, 12, 24, 48, 72, 96, 120, 144 and 168 hours.

(33) TABLE-US-00004 TABLE 4 Group V. alginolyticus double-stranded RNA D0 − DEPC-H.sub.2O D1 + DEPC-H.sub.2O D2 + dsRNA specific to tyrosine hydroxylase (SEQ ID NOS: 1 and 2) D3 + dsRNA specific to glyceraldehydes 3-phosphate dehydrogenase (SEQ ID NOS: 7 and 8) D4 + dsRNA specific to worm non-specific gene (SEQ ID NOS: 9 and 10)

(34) Referring to FIG. 4, at 168 hours post bacterial challenge, the cumulative mortality of white shrimps of group D0 is 0, and the cumulative mortality of white shrimps of groups D1, D3-D4 is about 70-80%. However, the cumulative mortality of white shrimps of group D2 decreases (about 50%), indicating the administration of the TH dsRNA effectively reduces the risk of death due to infection of V. alginolyticus in white shrimps.

(35) Accordingly, by administering the double-stranded RNA specific to tyrosine hydroxylase (TH dsRNA) to the shrimp body, immune parameters such as total haemocyte count and phenoloxidase activity are improved, phagocytic activity and clearance efficiency are increased, and mortality caused by attack of pathogens is decreased. With such performance, farmers can decrease the usage of antibiotics.

(36) Although the invention has been described in detail with reference to its presently preferable embodiment, it will be understood by one of ordinary skill in the art that various modifications can be made without departing from the spirit and the scope of the invention, as set forth in the appended claims.